Colon to Rectum

Aliment Pharmacol Ther. 2022;56(9):1361–9

Avni-Biron I, Mishael T, Zittan E, Livne-Margolin M, Zinger A, Tzadok R, Goldenberg R, Kopylov U, Ron Y, Hadar E, Helman S, Grisaru Granovsky S, Ollech JE, Arazi A, Farkash R, Pauker MH, Yanai H, Dotan I, Bar-Gil Shitrit A

Ustekinumab during pregnancy in patients with inflammatory bowel disease: A prospective multicenter cohort study

Background: Women with inflammatory bowel diseases (IBD) often receive biologics to maintain remission during pregnancy.
Aims: To assess maternal and neonatal outcomes in patients with IBD treated with ustekinumab (UST) during pregnancy.
Methods: In a multicenter, prospective cohort study, the authors recruited women with IBD treated with UST during pregnancy between 2019 and 2021. Outcomes were compared among patients treated with UST, anti-tumor necrosis factor alpha (anti-TNF), and non-UST, non-anti-TNF therapies. UST-treated patients were matched 1:2 to controls according to age, body mass index and parity. Newborns were followed up to 12 months.
Results: 129 pregnant patients were recruited: UST 27; anti-TNF 52; non-UST, non-anti-TNF 50 (thiopurine or mesalazine 30, no therapy 20); Crohn’s disease 25 (96.9%). Overall, pregnancy, neonatal and newborn outcomes were satisfactory, with no significant differences among patients treated with UST, anti-TNF and non-UST, non-anti-TNF agents for obstetrical maternal complications (UST 3 [11.5%], anti-TNF 12 [23.1%], non-UST, non-anti-TNF 4 [8.2%], p = 0.095), pre-term delivery (1 [4.3%], 9 [18.4%], 4 [5.7%], p = 0.133), low birth weight (1 [4.2%], 5 [10.2%], 4 [8.3%], p = 0.679), or first year newborn hospitalization (2 [9.1%], 4 [8.2%], 3 [6.1%], p = 0.885).

Conclusion: Pregnant patients with inflammatory bowel disease (IBD) treated with ustekinumab (UST) demonstrated favorable pregnancy and neonatal outcomes that were comparable with those in patients treated with anti-TNF or other therapy. Data are reassuring for patients with IBD and their physicians when considering UST during pregnancy.

Dr. A. Bar-Gil Shitrit, Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel,
E-Mail: ariellash@szmc.org.il

or

Dr. I. Avni-Biron, IBD Center, The Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel,
E-Mail: iritab@clalit.org.il

DOI: DOI: 10.1111/apt.17224

Back to overview

this could be of interest:

Colon to Rectum

Fecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild-to-moderate ulcerative colitis: A randomized controlled trial

Gut. 2022;71(12):2401–13

Colon to Rectum

Effect of colonoscopy screening on risks of colorectal cancer and related death

N Engl J Med. 2022;387(17):1547–56